Deep Breeze announces latest results on vibration response imaging (VRI)

10 October 2008

Deep Breeze Ltd, the developeer of the revolutionary pulmonary imaging technology, vibration response imaging (VRI), has announced the latest study results comparing VRI to conventional procedures of assessing regional lung function measurement.

Prof. Roberto Bossi, Chief of Center of Sleep respiratory disorders of Foundation IRCCS Ospedale Maggiore Policlinico University of Milano, presented his findings at the 18th European Respiratory Society Congress last week.

The study measured the effectiveness of VRI for the evaluation of lung function compared to functional respiratory tests, before and after thoracic surgery. Data showed that VRI allows better evaluation of lung volume regional variations after chest lobectomy compared to functional respiratory tests.

“The advantages having a non invasive, patient's effort independent, easy to handle and readily available imaging modality for pulmonology are numerous,” said Prof. Bossi. “A big benefit is that I can monitor and measure the gain or loss of lung function after chest surgery better than functional respiratory test.”

In addition, Deep Breeze has launched a strategic program to include the VRIxp as an integral part of the guidelines for physiologic evaluation of patients with lung cancer being considered for resectional surgery.

The feasibility of this program is currently being investigated by MD Anderson. The leading investigator of this program Prof. Rodolfo Morice said: "Lung cancer is the leading cause of cancer death in the USA and the world and surgery remains the best treatment option for patients with this condition. Predictions of postoperative lung function are crucial to maximize the number of patients that can benefit from surgery and identify patients with such poor respiratory reserve that lung resection would result in an unacceptable quality of life. These preoperative evaluations currently require radionuclide tests of ventilation and perfusion that require administration of radioactive isotopes and not always readily available.”

Deep Breeze is planning to market the VRIxp across Europe to Hospitals that conduct lung resection for patients with lung cancer. The initial launch happened in Spain in September and the company will expand their activities to other European countries by the end of 2008.

Results of an additional study that was conducted in a University department at the Asthma and Allergy Center of the Pulmonary Unit in Evgenidio Hospital, in Athens Medical School in Greece were also presented by Prof. Christina Gratziou at the Congress. The purpose of this study was to establish whether or not the VRIxp has a role to play in the early detection of airway obstruction in smokers.

The study population consisted of 25 healthy smokers, 23 known COPD patients and 10 healthy non-smokers. The initial findings of the study showed that in 95.7% of known COPD patients showed dynamic disturbances in their VRIxp image. Furthermore 64% of 'healthy smokers' demonstrated abnormalities in their VRIxp image.

Prof. Gratziou declared that “The initial findings of our study on a small population of 58 smoker subjects, is indicative of a potential role of the VRIxp as a screening tool of early detection of abnormalities due to smoking exposure. Smoker subjects can be monitored unlimitedly with documentable results that can be analyzed and given as a written report. Thus, the VRIxp can be useful also as an effective tool to educate patients on the harmful effects of smoking and furthermore to enhance motivation for quitting tobacco use”.

Bookmark this page  Reddit  StumbleUpon

To top